EMAIL US AT info@bcan.org
SUPPORT HOTLINE (888) 901-2226
Donate Now

Blog

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

The FDA has now approved Merck’s KEYTRUDA® (pembrolizumab) as a first-line treatment for patients who are cisplatin-ineligible diagnosed with locally advanced or metastatic urothelial carcinoma. Additionally, second-line treatment in patients who are platinum-ineligible and have disease progression during or following chemotherapy or within 12 months of neoadjuvant or adjuvant treatment

Read More

Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 Meeting

On Sunday, May 14th, at the American Urological Association (AUA) 2017 Meeting in Boston, MA, Photocure ASA announced the latest data from their Phase 3 study with Blue Light Flexible Cystoscopy (BLFC™) with Hexvix®/Cysview®. This study showed that in 21.5% of the patients undergoing surveillance cystoscopy, a bladder cancer recurrence

Read More

New Guidelines for Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer!

For the first time for any type of malignancy, the American Urological Association (AUA), the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) have formulated an evidence-based guideline for the treatment of non-metastatic muscle-invasive bladder cancer. BCAN Co-Founder,

Read More

BCAN Launches My Bladder Cancer Story

This year, over 81,000 people will be diagnosed with bladder cancer. BCAN understands that there are real people behind this number. Our ‘My Bladder Cancer Story’ Campaign presents stories to raise awareness and call attention to the lives and daily experiences of bladder cancer patients and families nationwide. Read My Bladder Cancer

Read More

12